Journal of Gastroenterology and Digestive Diseases

Journal Banner

HER2 Status Examination of Biopsy Specimens from Gastric Mucosa

Ooi Akishi*

Department of Molecular and Cellular Pathology Graduate School of Medical Science, Kanazawa University, Ishikawa 920-8641, Japan

*Corresponding Author:
Ooi Akishi
Department of Molecular and Cellular Pathology
Graduate School of Medical Science, Kanazawa University
Ishikawa 920-8641, Japan
Tel: 81-76-265-2192; E-mail: [email protected]

Received date: June 17, 2016; Accepted date: July 19, 2016; Published date: July 22, 2016

Visit for more related articles at Journal of Gastroenterology and Digestive Diseases

Abstract

ERBB2 (also called HER2) is a 185 kDa transmembrane tyrosine kinase receptor. Overexpression as a result of HER2 gene amplification on chromosome 17q11.2-q12 has been observed in solid tumors including gastric and breast cancers1. HER2 is amplified in 7%-20% of gastric cancers2-5. Overexpressed HER2 is a therapeutic target of Trastuzumab, a humanized monoclonal antibody that binds to the extracellular juxtamembrane domain of ERBB2 and inhibits the proliferation and survival of HER2-overexpressing cancer cells6 (Figure 1).

Keywords

Erbb2, Gastric cancer, Mucosal biopsy, IHC, FISH

Letter to Editor

ERBB2 (also called HER2) is a 185 kDa transmembrane tyrosine kinase receptor. Overexpression as a result of HER2 gene amplification on chromosome 17q11.2-q12 has been observed in solid tumors including gastric and breast cancers [1]. HER2 is amplified in 7%-20% of gastric cancers [2-5]. Overexpressed HER2 is a therapeutic target of Trastuzumab, a humanized monoclonal antibody that binds to the extracellular juxtamembrane domain of ERBB2 and inhibits the proliferation and survival of HER2-overexpressing cancer cells [6] (Figure 1).

gastroenterology-and-digestive-diseases-Gastric-mucosal-biopsy

Figure 1: Gastric mucosal biopsy (A) and HER two brother tests, HER2-IHC (B) and HER2-FISH. Portions of the FISH image was modified.

A critical factor in determining patient eligibility and predicting outcomes of this therapy is the intratumoral heterogeneity of HER2 amplification in gastric adenocarcinomas [7]. In adjuvant therapy, precise examination of the resected specimen was possible. In neoadjuvant therapy, endoscopic mucosal biopsy was the only test to know the eligibility of this molecular target study. Recently Ahn et al. compared HER2 expression in 702 paired biopsy and resection specimens of gastric cancer by immunohistochemistry (IHC) [8] . They concluded four fragments should be obtained to minimize the differences in HER2 scores between biopsy and resection specimens. In their study HER2 positivity was decided only by IHC; and their IHC images were consummate and their HER2 positive rates were well acceptable. However, it is well known that there are many unequivocal IHC judgements (2+) not only on surgical materials but also on biopsy specimens. Thus, I think when HER2-positive gastric cancer is suspicious, two brother’s tests, IHC and FISH, are mandatory.

References